| TRADING CENTER |
| 5 Stocks Approaching Greatness - MotleyFool.com | |
| 5 Superball Stocks - MotleyFool.com | |
| Stock Smackdown: Cramer vs. CAPS - MotleyFool.com | |
| Allos Therapeutics' FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of... - Business Wire | |
| Stock Watch: StockPreacher.com Issues Market Alert for Allos Therapeutics Inc. - GlobeNewswire | |
| Celgene to buy Gloucester in cancer drug deal - Reuters | |
| Allos Therapeutics' FOLOTYN™ Demonstrates Activity in Patients with Relapsed o... - Business Wire | |
| Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for F... - Business Wire | |
| Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymp... - Business Wire | |
| Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.42 | 0.00 / 0.00% | 10.98 |
| GILD | Gilead Sciences Inc | 43.00 | 0.00 / 0.00% | 16.60 |
| CELG | Celgene Corporation | 56.38 | 0.00 / 0.00% | 67.93 |
| 2008 Revenue: | $0.0 | Headquarters: Westminister, CO |
| Employees: | 81 | CEO: Paul L. Berns |
| Net Income: | $-51,729,913.0 | Industry: Biotechnology |
| Market Cap: | $664.2 M | Website: www.allos.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| ALTH | 6.39 | 0.00 / 0.00% | 6.39 | 0.00 | 0.00 | Profile Chart News |